SKK
RVNC

Shepherd Kaplan Krochuk’s Revance Therapeutics, Inc. RVNC Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-7,196
Closed -$222K – 261
2018
Q1 		$222K Hold
7,196
– – 0.13% 181
2017
Q4 		$257K Buy
+7,196
New +$207K 0.16% 162

Other funds holding RVNC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Shepherd Kaplan Krochuk's RVNC Position: Q2 2018 in Review

Shepherd Kaplan Krochuk sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2018, closing a stake of 7,196 shares — an estimated $222K sold.

Shepherd Kaplan Krochuk first reported a position in RVNC in Q4 2017 and held it in 2 quarters. The position peaked at $257K in Q4 2017. 110 funds tracked by Wall St. Rank hold RVNC as of Q2 2018.

  • Shepherd Kaplan Krochuk reported no remaining Revance Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 7,196 Revance Therapeutics, Inc. shares in Q2 2018, an estimated $222K.
  • Shepherd Kaplan Krochuk first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 2 quarters.
  • Shepherd Kaplan Krochuk's Revance Therapeutics, Inc. position peaked at $257K in Q4 2017.
  • 110 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2018.

Based on Shepherd Kaplan Krochuk's 13F filing for Q2 2018, filed 14 Aug 2018.